Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP – at baseline
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047–53
Dorner T, Rathmanner T, Lechleitner M, Schlogel R, Roden M, Lawrence K, et al. Public health aspects of diabetes mellitus–epidemiology, prevention strategies, policy implications: the first Austrian diabetes report. Wien Klin Wochenschr 2006;118(17–18):513–9
Rakovac I, Plank J, Jeitler K, Beck P, Seereiner S, Mrak P, et al. Health status of type 2 diabetics in Austria – perspective of a quality improvement initiative. Wien Med Wochenschr 2009;159(5–6):126–33
Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002;45(7):S1–4
Muhlhauser I, Sulzer M, Berger M. Quality assessment of diabetes care according to the recommendations of the St. Vincent declaration: a population-based study in a rural area of Austria. Diabetologia 1992;35(5):429–35
Gerlach FM, Beyer M, Szecsenyi J, Raspe H. Evaluation of disease management programs–current deficits, demands and methods. Z Arztl Fortbild Qualitatssich 2003;97(7):495–501
Ecker J, Witzmann G, Gmeiner H, Aigner I, Said H. Structured treatment of diabetes in the country. Wien Med Wochenschr 2005;155(15–16):371–5
Buntin MB, Jain AK, Mattke S, Lurie N. Who gets disease management? J Gen Intern Med 2009;24(5):649–55
Dunkelberg S, Zingel D, Noack A, van den BH, Kaduszkiewicz H. Which patients are (not) included in the DMP diabetes programme?. Gesundheitswesen 2006;68(5):289–93
Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A, et al. Interventions used in disease management programmes for patients with chronic illness – which ones work? Meta-analysis of published reports. Br Med J 2002;325(7370):925–8F
Ofman JJ, Badamgarav E, Henning JM, Knight K, Gano AD, Levan RK, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004;117(3):182–92
Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323(7319):970–5
Sonnichsen AC, Rinnerberger A, Url MG, Winkler H, Kowatsch P, Klima G, et al. Effectiveness of the Austrian disease-management-programme for type 2 diabetes: study protocol of a cluster-randomized controlled trial. Trials 2008;9:38
Sonnichsen AC, Winkler H, Flamm M, Panisch S, Kowatsch P, Klima G, et al. The Effectiveness of the Austrian Disease Management Programme for Type 2 Diabetes: a Cluster-Randomised Controlled Trial. BMC Fam Pract 2010;11(1):86
Österreichische Diabetes Gesellschaft. Diabetes mellitus – guidelines for the practice. Revised and expanded 2007 edition. Wien Klin Wochenschr 2009;121(Suppl. 5):S1–87
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604–12
IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005
National Collaborating Center for Chronic Conditions. Type 2 diabetes: national clinical guidelines for management in primary and secondary care (update). London: Royal College of Physicians, 2008
NICE clinical guideline 34. Hypertension: management of hypertension in adults in primary care. Published by the National Institute for Health and Clinical Excellence, 2006
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl. 2:E1–40
UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854–65
UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53
Williams R, Van GL, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45(7):S13–7
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141(6):421–31